Daiichi Pharmaceutical Concludes Joint Promotion of Plavix (R) with Sanofi-aventis

For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshio Takahashi, Corporate Officer in Charge, Corporate Communications Department Telephone: +81-3-6225-1126 http://www.daiichisankyo.co.jp/ Daiichi Pharmaceutical Concludes Joint Promotion of Plavix (R) with Sanofi-aventis Tokyo, March 1, 2007-DAIICHI SANKYO COMPANY, LIMITED announced today that its fully owned subsidiary Daiichi Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President: Kiyoshi Morita) has concluded its agreement with sanofi-aventis K.K. (Headquarters: Tokyo; President & Representative Director: Philippe Fauchet) for the joint promotion of the antiplatelet agent Plavix® as of February 28, 2007. End

The release as fetched from its publisher. daiichisankyo.com ↗